SCHEMBL16201371

SCHEMBL16201371

CCCN(C)Cc1n[nH]cc1-c1ccc(C(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
RAB9A P51151 1/20 0.39
PRMT3 O60678 1/20 0.34
CARM1 Q86X55 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
PRMT1 Q99873 1/20 0.34
PRMT8 Q9NR22 1/20 0.34
NISCH Q9Y2I1 1/20 0.33
CMKLR1 Q99788 8/20 0.32
CXCR4 P61073 3/20 0.32
AGTR1 P30556 2/20 0.32
AGTR2 P50052 2/20 0.32
PYCR1 P32322 1/20 0.32
NOTUM Q6P988 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CASR P41180 1/20 0.31
ERBB2 P04626 1/20 0.31
UCHL3 P15374 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201191 0.88 CARM1 (0.46) NPSR1NPC1TP53RAB9APRMT3
SCHEMBL16201380 0.86 CRHR1 (0.36) NPC1PRMT3CARM1PRMT6PRMT1
SCHEMBL16201425 0.85 AGTR1 (0.35) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201340 0.84 TDO2 (0.33) AGTR1AGTR2PYCR1ALDH1A1
SCHEMBL16201443 0.81 PRMT6 (0.45) PRMT6PRMT1PRMT8
SCHEMBL16201384 0.81 PRMT3 (0.40) RAB9APRMT3CARM1PRMT6PRMT1
SCHEMBL16201358 0.81 PRMT6 (0.39) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16201349 0.81 HRH3 (0.43) ALDH1A1
SCHEMBL16201372 0.80 SPHK1 (0.33) AGTR1AGTR2NOTUM
SCHEMBL16201444 0.80 LTA4H (0.41) NISCHAGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 NPSR1 4207/4885NPC1 631/4885TP53 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.